Priority 22 from the Liver Glycogen Storage Disease (International) PSP

UNCERTAINTY: Which is the role and use of medium-chain triglycerides (MCT) in the management of different patients with liver Glycogen Storage Disease?  (JLA PSP Priority 22)
Overall ranking 22
JLA question ID 0090/22
Explanatory note

There is much debate in literature on the indication and effect of MCT treatment for patients which liver GSD. This question illustrates that more research is needed into the treatment effects.  
Evidence

For details of the evidence checked, please see the spreadsheet held on the JLA website.
Health Research Classification System category  Metabolic and endocrine 
Extra information provided by this PSP
Original uncertainty examples Do MCT diets help cardiomyopathy in GSD 111 ~ Is there a role for MCT in the management of GSD1? ~ Does the addition of MCT help in treatment?  
Submitted by Patient, carer and healthcare professionals 
PSP information
PSP unique ID 0090
PSP name International Glycogen Storage Disease PSP
Total number of uncertainties identified by this PSP 72  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 24 May 2019